WASHINGTON: A top Indian official has asked the G20 nations to cooperate and concentrate on evidence-based research ahead of the biennial India-U.S. BioPharma and Healthcare Summit, which will be attended by scientists, academicians, corporate executives, and representatives from both countries.
Kant said, India's G20 Sherpa, was quoted in a statement by the USA-India Chamber of Commerce (USAIC) on Sunday as saying, "I urge G20 member countries, businesses, academics, and scientists to collaborate and focus on evidence-based research and analytics to ensure preparedness in health systems and build adaptable global supply chains that can deliver instantly during a crisis." The 17th annual BioPharma and Healthcare Summit will be held virtually on May 3rd, according to the USAIC. All G20 members are equally responsible for establishing stable, resilient health systems that guarantee individuals' access to healthcare, he said.
Through research, innovation, partnership, and collaboration, he said, the G20's Research and Innovation Initiative Gathering (RIIG), Science20, and Startup20 seek to achieve socio-economic equity.
"Global collaboration and partnership in drug and vaccine development, clinical research, streamlining workflows, and inventory management will mitigate risks and allow seamless delivery of health care services," declared Kant, who would be addressing the conference alongside other Indian government officials and business leaders, including Kiran Mazumdar Shaw, Dr. Naresh Trehan, Dr. Shiv Sarin, and Dr. Krishna Ella. Dr. Robert Califf, commissioner of the US FDA, will attend the meeting.
Joaquin Duato, the Chairman and CEO of Johnson & Johnson, Albert Bourla, the Chairman and CEO of Pfizer, Christopher Viehbacher, Kenneth Frazier, the former Chairman and CEO of Merck, and other significant participants include top venture capitalists, academic leaders from Harvard, MIT, MD Anderson, and Takeda, Sanofi, Amgen, Novartis, Eli Lilly, and Novo Nordisk, who represent the interest of international biopharmaceutical companies in Andrew Plump, president of Reserach and Develoopment Takeda, and Chair, of USAIC BioPharma and Healthcare Summit said, the extraordinary advancements in healthcare brought about by the pace of scientific innovation over the past few decades must be made available to everyone in the world. 'This year, with India on track to overtake China as the world's most populous nation, our responsibility to ensure that its people benefit from these innovations that improve human health has never been greater." he said
"In the upcoming years, India will undoubtedly emerge as a leader in biopharmaceutical innovation. In terms of biopharmaceutical and healthcare innovation, India has both great needs and great potential. Karun Rishi, president of USAIC, stated, "We are really delighted to see strong development and promising signals of India adopting BioPharma innovation after 17 years of constant efforts by the USAIC.
"In order to promote innovation and attract much-needed investment, India has implemented a number of practical initiatives that will help the nation become a leader in R&D. The Indian government has taken steps in recent years to lay the groundwork for R&D in India. Now, whether in R&D, translational research, industry-academic partnerships, clinical trials, or manufacturing, we should work towards scaling it up, he said.
He added that biopharmaceutical firms are using cloud-based technologies, artificial intelligence, machine learning, and other digital solutions to digitise their operations, which is altering how we find, create, and distribute health innovation.
India will benefit greatly from this. India possesses the skills, facilities, and potential to make a significant contribution to the field of data science and digital technology, said Karun Rishi, president of USAIC
"With India taking up the G20 Presidency this year, it is important to intensify the conversation regarding biopharmaceutical research and development, clinical trials, and the global supply chain. Amitabh Kant, the G20 Sherpa, and other business executives will participate in a special session at the summit to talk about this. G20 is an extremely potent organisation. The open discussion of access and availability as a top priority for fair access to biopharmaceutical innovation is crucial for India and the rest of the world, said Rishi.
"How can the business community and G20 leaders collaborate to make this happen? The healthcare issues of today are complicated. The effectiveness of a global response will be greater than that of individual nation-state responses. This year's G20 leadership by India might be a turning point in addressing these vital challenges for patients all across the world, he said.
Hari Bhartia, the founder and co-chairman of Jubilant Bhartia Group, believes that India has a fantastic chance to take use of its long history in the pharmaceutical industry to diversify into biologics and biosimilars.
With a wide range of competent people pools, top-notch infrastructure, and pro-business laws, it offers a suitable climate for growing biotechnology and healthcare firms. The nation has made significant investments in infrastructure, including cutting-edge manufacturing facilities with international accreditations and cutting-edge laboratories with cutting-edge technology to assist drug discovery and development research, he siad.."India's strategic shift towards biopharmaceutical innovation is good news for patients everywhere. It will be crucial in creating high-quality therapy products at a reasonable cost thanks to international partnerships, Bhatia continued.
USAID is providing free registration for the annual summit in an effort to promote innovation and support the sector. Due to this, the annual summit has drawn more than a thousand medical researchers and students from around the world. "The response from my younger colleagues gives me hope. They will be the industry's future leaders in healthcare and life sciences. It said we must take every possible step to support the upcoming leaders.
G20 preparations are in full swing as Srinagar, Details Inside
Pak started dirty game before G20 meeting, gathering of terrorists near LoC